Home - Open Targets

Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or Open Targets Genetics which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.

Find targets for a given disease
Visit the Open Targets Platform Discover genetic evidence for targets
Visit Open Targets Genetics Explore our research projects
Read our publications

News

A tumoroid, colon cancer cells grown in 3D

Cancer drug resistance causes and categories identified

18 October 2024

Researchers have mapped the genetic landscape of cancer drug resistance, uncovering that DNA changes can be grouped into four main categories and highlighting possible new therapeutic targets.

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.

In a new large-scale study, re...

Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.